ISIS 416858: Clinical Trials

2 trials of ISIS 416858, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2

Follow ISIS 416858: new trials by email Literature Review of ISIS 416858 trials Research Report on ISIS 416858

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
ISIS 416858, Placebo - End-stage Renal Disease (ESRD)
Phase 2CompletedIonis Pharmaceuticals, Inc.2132017-12-262023-01-20
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
ISIS 416858, Placebo - End-stage Renal Disease (ESRD)
Phase 2CompletedIonis Pharmaceuticals, Inc.492015-10-012016-12-13

Conditions studied

Kidney Failure, Chronic (2)

Sponsors

Ionis Pharmaceuticals, Inc. (2)

Countries

Canada (1)  ·  Spain (1)

Top investigators

Sanjay Bhanot, MD (1)

Results publications

PMID 35155859, PMID 38189593

NIH funding

2017 (1)